Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ) has announced that it recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for its innovative drug, HSK51155 tablets.

HSK51155 is an orally administered small-molecule analgesic drug independently developed by the company with its own intellectual property rights. It is clinically intended for the treatment of migraines.

The drug aims to effectively control pain while reducing the occurrence of adverse reactions and avoiding the risk of addiction, offering patients a safer and more effective option for pain management.